CorMedix Inc. Announces New Commercial Agreement To Provide Access To DefenCath For Adult Patients With Kidney Failure Receiving Hemodialysis Through A Central Venous Catheter At More Than 250 Outpatient Dialysis Clinics Located Across The United States
Portfolio Pulse from Benzinga Newsdesk
CorMedix Inc. has signed a new commercial agreement to supply DefenCath to over 250 outpatient dialysis clinics in the US, expanding its market reach. The product, approved under the LPAD pathway, is set to begin shipments in Q4 2024.
September 19, 2024 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CorMedix Inc. has secured a new commercial agreement to supply DefenCath to over 250 outpatient dialysis clinics in the US. This expansion follows the product's approval and reimbursement by CMS, with shipments starting in Q4 2024.
The new commercial agreement significantly expands CorMedix's market reach for DefenCath, a product recently approved and reimbursed by CMS. This is likely to positively impact CRMD's stock price as it indicates growth in sales and market penetration.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100